Would you recommend buying alt stock for the July? Do deep analysis and check everything

**Altimmune Inc. (ALT)** is a biotech stock that has garnered attention due to its recent positive trial results and potential for regulatory approval. However, the decision to buy ALT for July 2025 should be approached with caution, considering both the bullish indicators and the inherent risks in the biotech sector. Here's a deep analysis to inform your decision:

1. **Technical Indicators**:
- **MACD**: ALT's MACD is -0.76, indicating bearish momentum. However, this could also suggest that the stock is oversold and due for a potential reversal.
- **RSI**: The RSI is 32.75, which is neither overbought nor oversold. This suggests that the stock has room for movement in either direction.
- **KDJ**: The KDJ is 7.31, which is quite low and typically indicates an oversold condition. This could be a sign of a potential reversal or a buying opportunity.
- **BOLL**: ALT is trading near the lower band of its BOLL, which could be a sign of a potential bounce back up.
- **Moving Averages**: The stock is above its 5-Day, 10-Day, and 20-Day moving averages, indicating a short-term uptrend. However, it is below its 30-Day, 50-Day, and 60-Day moving averages, suggesting a longer-term downtrend.
- **Long-term Moving Averages**: It is above its 120-Day, 200-Day, and 250-Day moving averages, indicating a strong long-term uptrend.

|code|Ticker|Name|Date|Moving Average|market_code|
|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|20250701|4.5840|185|

|code|Ticker|Name|Date|Boll|RSI|KDJ|MACD|market_code|
|---|---|---|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|20250701|5.9980|32.7514|7.3119|-0.7585|185|

2. **Fundamental Analysis**:
- **Financial Performance**: ALT reported a net loss of $19.58 million and a diluted EPS of -$0.26 for the latest quarter. The company's revenue was $5 million, which may not be sufficient to cover expenses.
- **Growth Rates**: The company has a negative net income growth rate of 19.75% and a negative diluted EPS growth rate of 23.53%. This indicates a challenging financial period.
- **Analyst Sentiment**: There are mixed analyst ratings, with some analysts setting a high price target of $25, indicating potential upside. However, other analysts have set lower targets, reflecting differing views on the stock's future performance.
- **Technical Patterns**: ALT has been identified with bullish patterns like the Bullish Engulfing and Piercing Pattern, which can be seen as positive signals for potential upward movement.
3. **Current News and Events**:
- **Trial Results**: ALT announced positive topline data from its 24-week Phase 2b IMPACT trial evaluating pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). This could be a significant catalyst for the stock.
- **Regulatory Progress**: The company is preparing to advance to Phase 3 trials and is scheduled to meet with the FDA in the fourth quarter of 2025. These events could influence the stock's trajectory.
- **Stock Performance**: ALT has experienced significant volatility, with a recent 48.65% decline over the past week, which may reflect market uncertainty or reaction to the mixed trial results.
4. **Market Sentiment and Valuation**:
- **Market Sentiment**: The stock has seen a significant drop after the trial results, which may indicate a need for time to recover.
- **Valuation**: ALT's P/E ratio is extremely high at 15694.2, suggesting that the stock may be overvalued based on its current earnings. The P/S ratio is 3.3, and the Price to Book Ratio is 15694.2, further supporting the notion of high valuation.

|code|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio|market_code|
|---|---|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|20240701|-5.514171|25576.65612|2.9519176069898285|185|
|ALT|ALT.O|Altimmune|20240702|-5.161876|23942.591979|2.763322870987701|185|
|ALT|ALT.O|Altimmune|20240703|-5.054656|23445.26811|2.7059244730740093|185|
|ALT|ALT.O|Altimmune|20240705|-5.069974|23516.314377000002|2.714124244204537|185|
|ALT|ALT.O|Altimmune|20240708|-5.276755|24475.4389815|2.824821154466655|185|
|ALT|ALT.O|Altimmune|20240709|-5.284414|24510.962115000002|2.8289210400319194|185|
|ALT|ALT.O|Altimmune|20240710|-5.728611|26571.303858000003|3.066714402817211|185|
|ALT|ALT.O|Altimmune|20240711|-5.881782|27281.766527999996|3.148712114122484|185|
|ALT|ALT.O|Altimmune|20240712|-6.050271|28063.275465|3.238909596558284|185|
|ALT|ALT.O|Altimmune|20240715|-6.050271|28063.275465|3.238909596558284|185|

5. **Risks and Uncertainties**:
- **Trial Variability**: There is variability in the biopsy results from the IMPACT trial, which could affect the timeline and outcomes.
- **Financial Health**: Despite strong cash reserves, the company has significant net losses and negative EPS growth rates, which are red flags for investors.

**Conclusion**: Based on the analysis, ALT is a stock with both potential and risks. The technical indicators show a mixed signal, with short-term uptrends but longer-term downtrends. The fundamentals indicate a challenging financial period, and the valuation is high. The news and events suggest that the company has potential with its trial results and regulatory progress, but the market sentiment and variability in trial results pose uncertainties.

If you are considering a short-term trade and are comfortable with high risk for potential high rewards, ALT might be worth a look, especially in light of the positive trial results. However, if you prefer a safer investment or have a longer-term horizon, you might want to wait for clearer signs of stability and growth. It's important to align this decision with your investment strategy, risk tolerance, and the time horizon of your investment goals.

|code|Ticker|Name|Date|Closing Price|market_code|
|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|20250701|4.23|185|

|code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|2024 Q2|-53.415104912521016|-16.666666666666664|-9.374999999999991|185|
|ALT|ALT.O|Altimmune|2024 Q3|-10.517149629916307|-98.61878453038673|17.94871794871795|185|
|ALT|ALT.O|Altimmune|2024 Q4|26.74062134572232|-86.48648648648648||185|
|ALT|ALT.O|Altimmune|2025 Q1|19.754857751906208|0|23.529411764705884|185|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|2024 Q2|-53.415104912521016|-2.464E7|185|
|ALT|ALT.O|Altimmune|2024 Q3|-10.517149629916307|-2.2845E7|185|
|ALT|ALT.O|Altimmune|2024 Q4|26.74062134572232|-2.318E7|185|
|ALT|ALT.O|Altimmune|2025 Q1|19.754857751906208|-1.9575E7|185|

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|2024 Q2|-16.666666666666664|5000|185|
|ALT|ALT.O|Altimmune|2024 Q3|-98.61878453038673|5000|185|
|ALT|ALT.O|Altimmune|2024 Q4|-86.48648648648648|5000|185|
|ALT|ALT.O|Altimmune|2025 Q1|0|5000|185|

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|2024 Q2|-9.374999999999991|-0.35|185|
|ALT|ALT.O|Altimmune|2024 Q3|17.94871794871795|-0.32|185|
|ALT|ALT.O|Altimmune|2025 Q1|23.529411764705884|-0.26|185|